# High-THC Cannabis Increased Inflammation Without Improving Insulin Sensitivity > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/high-thc-cannabis-increased-inflammation-without-improving-insulin-sensitivity/ > **Published:** 2026-08-15T12:21:35-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:47:29-04:00 > **Clinical Summary:** High-THC cannabis linked to increased inflammation without improving insulin sensitivity. Clinical guidance for metabolic patients. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. THCResearchSafetyDosingPolicyPainAnxiety Why This Matters Clinicians treating patients with diabetes or [metabolic syndrome](https://cedclinic.com/cannabidiol-fatty-liver-disease-research-insights/) should be aware that high-THC [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) may increase inflammatory markers without providing metabolic benefits, potentially worsening disease outcomes in this population. This finding is particularly relevant for patients who use cannabis believing it aids glucose control, as the evidence suggests high-THC products could be counterproductive for [metabolic health](https://cedclinic.com/cannabis-compounds-reverse-fatty-liver-disease/). Practitioners should counsel patients on these risks and consider inflammatory and glucose metrics when assessing [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in metabolically vulnerable patients. Clinical Summary This study found that acute exposure to high-THC cannabis increased inflammatory markers without producing improvements in insulin sensitivity, suggesting potential metabolic risks from high-potency products. The researchers observed a significant interaction between duration of exposure and peak blood THC levels, indicating that higher THC concentrations were associated with greater inflammatory responses. These findings are particularly relevant for patients with metabolic disorders, diabetes, or obesity who may turn to cannabis for symptom relief, as the inflammatory effects could counteract potential [therapeutic benefits](https://cedclinic.com/therapeutic-benefits-of-thc/) and worsen [metabolic health](https://cedclinic.com/cannabis-compounds-reverse-fatty-liver-disease/). Clinicians should be aware that the increased potency of modern cannabis products may carry metabolic downsides not present in lower-THC formulations. Patients considering [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), especially those with insulin resistance or inflammatory conditions, should discuss the potential metabolic risks with their healthcare provider and consider lower-THC alternatives if cannabis use is pursued. Dr. Caplan’s Take “What we’re seeing in this work is a concerning signal that needs replication in larger, longer studies before we can draw firm clinical conclusions, but the mechanistic finding around THC exposure and inflammatory markers is worth taking seriously in our counseling conversations with patients, particularly those managing metabolic conditions.” Clinical Perspective 💉 This laboratory finding of increased systemic inflammation with high-THC cannabis exposure is clinically relevant given the rising prevalence of high-potency products, particularly among patients with metabolic concerns. However, clinicians should note several important caveats: the study measures acute inflammatory markers in a controlled setting, which may not translate directly to chronic users or real-world consumption patterns, and individual variation in [cannabinoid metabolism](https://cedclinic.com/fatty-acid-amide-hydrolase-obesity-risk-genetic-links/), route of administration, and baseline metabolic health could substantially modify these effects. The failure to observe improvements in insulin sensitivity is noteworthy for patients with diabetes or prediabetes who may believe cannabis offers metabolic benefits, though long-term effects remain understudied. When counseling patients about cannabis use, particularly those at risk for or managing metabolic disease, practitioners should acknowledge this emerging evidence while discussing the dose-response relationship and recommending lower-THC alternatives if cannabis use is being considered. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20High-THC%20Cannabis%20Increased%20Inflammation%20Without%20Improving%20Insulin%20Sensitivity%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73495)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73495)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20High-THC%20Cannabis%20Increased%20Inflammation%20Without%20Improving%20Insulin%20Sensitivity%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73495)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Daily Cannabis News Brief: Cannabidiol and Intestinal Protection](https://cedclinic.com/cannabidiol-antioxidant-intestinal-protection/) - [In the Mix: 37 More Articles — June 22, 2026](https://cedclinic.com/mixed-cannabis-industry-articles-june-22-2026/) - [Cannabis, Inflammation, and Anxiety: What the Research Shows](https://cedclinic.com/cannabis-inflammation-anxiety-sleep/) 📰 Source: [https://www.cannawize.co/high-thc-cannabis-inflammation-insulin-sensitivity-study](https://www.cannawize.co/high-thc-cannabis-inflammation-insulin-sensitivity-study) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).